Justin Renz serves as the Chief Financial and Operations Officer at Ardelyx, Inc., a biopharmaceutical company focused on developing innovative first-in-class medicines to enhance the lives of patients with unmet medical needs. Renz has been instrumental in steering the company's financial and operational strategies, playing a key role in its growth and development. His expertise in financial management and operations has been vital in navigating the complex landscape of pharmaceutical development and commercialization. Prior to joining Ardelyx, Renz held significant positions that honed his skills and prepared him for his current role. He previously served as the Chief Financial Officer at Relypsa, Inc., where he was pivotal in leading the company through its initial public offering and subsequent acquisition by Galenica. His strategic financial planning and execution were crucial in these milestones. Before Relypsa, Renz worked at Lehman Brothers as a Vice President in the Healthcare Investment Banking Group, where he advised on numerous mergers, acquisitions, and financings within the healthcare sector. His background in investment banking provided him with a deep understanding of the financial intricacies involved in the biotech industry. At Ardelyx, Renz's responsibilities extend beyond traditional CFO duties. He oversees the company’s operational activities, ensuring that Ardelyx's day-to-day functions align with its long-term strategic goals. His leadership has been essential in advancing the company’s pipeline, particularly in the development and commercialization of treatments for cardiorenal diseases. Under his guidance, Ardelyx has made significant strides in bringing innovative therapies to market, demonstrating his commitment to improving patient outcomes and driving shareholder value.